Thrive
Coming in six months after its $26 million Series A round, Headway now boasts $103 million in total funding and a new valuation of $750 million.
The results will not impact the current rollout of a new version of the app, under special FDA guidelines.
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia.